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Frontotemporal lobar degeneration (FTLD), the most frequent neurodegenerative disorder
with a presenile onset, presents with a spectrum of clinical manifestations, ranging from
behavioral and executive impairment to language disorders and motor dysfunction. Familial
aggregation is frequently reported, and about 10% of cases have an autosomal dominant
transmission. Microtubule associated protein tau (MAPT ) gene mutations have been the
ﬁrst ones identiﬁed and are associated with early onset behavioral variant frontotemporal
dementia phenotype. More recently, progranulin gene (GRN ) mutations were recognized
in association with familial form of FTLD. In addition, other genes are linked to rare cases
of familial FTLD. Lastly, a number of genetic risk factors for sporadic forms have also been
identiﬁed. In this review, current knowledge about mutations at the basis of familial FTLD
will be described, together with genetic risk factors inﬂuencing the susceptibility to FTLD.
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NEW DIAGNOSTIC CRITERIA OF FRONTOTEMPORAL LOBAR
DEGENERATION
Frontotemporal lobar degeneration (FTLD) represents a common
cause of dementia in subjects under 65 years. The age at onset
is typically 45–65 years, with a mean average in the 50s, and the
prevalence is equal among men and women. It is associated with
frontal and temporal lobe atrophy, involving the right and left
hemispheres, in some cases asymmetrically (Rosen et al., 2006).
It can be classiﬁed into two main cognitive syndromes (Neary
et al., 1998): behavioral variant frontotemporal dementia (bvFTD)
and primary progressive aphasia (PPA), whose diagnostic criteria
have been recently revised including neuroimaging and genetics
(Gorno-Tempini et al., 2011; Rascovsky et al., 2011).
Behavioral variant frontotemporal dementia is the most fre-
quent FTLD phenotype, characterized by behavioral alterations,
such as disinhibition, overeating, and impulsiveness, and impair-
ment of cognitive functions, with relative sparing of memory
(Hou et al., 2004). Changes in social behavior, loss of empa-
thy, and impairment of social insight are early and consistent
symptoms of bvFTD, whose importance and role for the early
diagnosis has been emphasized in the new consensus criteria (Ras-
covsky et al., 2011). According to these criteria, bvFTD main
feature is the progressive deterioration of behavior and/or cog-
nition by observation or history. If this criterion is satisﬁed, there
are three further levels of certainty for bvFTD: possible, probable,
or deﬁnite. “Possible” bvFTD requires three out of six clinically
discriminating features (disinhibition, apathy/inertia, loss of sym-
pathy/empathy, perseverative/compulsive behaviors, hyperorality,
and dysexecutive neuropsychological proﬁle). “Probable” bvFTD
meets the criteria of “possible” bvFTD plus (1) a signiﬁcant func-
tional decline (by caregiver report or evidenced at neuropsycho-
logical testing) (2) frontal and/or anterior temporal atrophy on
MRI or CT, or frontal and/or anterior temporal hypoperfusion or
hypometabolism on PET or SPECT. “Deﬁnite” bvFTD imply the
histopathological evidence of FTLD on biopsy or post mortem or
the presence of a known pathogenic mutation. These new criteria
have a ﬂexible structure to account for the high heterogeneity at
initial presentation.
Early and progressive changes in language functions rep-
resent the alternative presentation of FTLD. Progressive loss
of speech, with hesitant, non-ﬂuent speech output with pho-
netic/phonological errors, and distortions and/or agrammatism is
typical of primary non-ﬂuent aphasia (PNFA) subtype (Scarpini
et al., 2006), whereas loss of knowledge about words and objects,
anomia and single-word comprehension deﬁcits are core features
of the semantic variant of PPA, named semantic dementia (SD;
Gorno-Tempini et al., 2011). A third subtype of PPA has been
recently described as logopenic or phonological variant (LPA). It is
characterized by phonological disorders, defective word retrieval,
and sentence repetition deﬁcits. This PPA subtype seems to be
associated with underlying Alzheimer’s disease (AD) pathology
(Rabinovici et al., 2008).
GENETICS: AUTOSOMAL DOMINANT MUTATIONS
The presence of familial aggregation and the autosomal domi-
nant transmission of the disease suggested so far a genetic cause
(Snowden et al., 2002; Bird et al., 2003; Goldman et al., 2005). Up
to 40%of patients have a family history suggesting FTLD in at least
one extra family member (Goldman et al., 2005; Pickering-Brown,
2007), with a percentage of autosomal dominant cases accounting
for 13.4% of the total (Goldman et al., 2005).
New criteria for bvFTD diagnosis (Rascovsky et al., 2011)
include the presence of a known mutation as a biomarker.
The demonstration of an autosomal dominant mutation is
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requested for the diagnosis of “deﬁnite” bvFTD, and is the only
criterion existing so far to make a deﬁnite diagnosis during
life. Genes demonstrated to be responsible for familial FTLD
include: microtubule associated protein tau (MAPT ) gene, pro-
granulin (GRN ), valosin-containing protein (VCP)-1, chromatin-
modifying 2B (CHMP2B),TAR-DNAbinding protein 43 encoding
gene (TARBDP), and, very recently, a novel hexanucleotide expan-
sion in chromosome 9 (Dejesus-Hernandez et al., 2011; Renton
et al., 2011).
MICROTUBULE ASSOCIATED PROTEIN TAU GENE
The ﬁrst evidence of a genetic cause for familial FTLD came
from the demonstration of a linkage with chromosome 17q21.2
in autosomal dominantly inherited form of FTD with parkin-
sonism (Lynch et al., 1994) resulting in the label of “frontotem-
poral dementia and parkinsonism linked to chromosome 17”
(FTDP-17). The gene responsible for such association, named
MAPT gene, was discovered few years later (Hutton et al., 1998;
Poorkaj et al., 1998; Spillantini et al., 1998). MAPT encodes the
microtubule associated protein Tau, which is involved in micro-
tubule stabilization and assembly. To date, more than 40 path-
ogenic MAPT mutations have been described in 134 families
(http://www.molgen.ua.ac.be/). MAPT mutations can be non-
synonymous, deletions, or intronic mutations located close to the
splice-donor site of the intron after the alternatively spliced exon
10 (Rademakers et al., 2004). They aremainly clustered in exons 9–
13, which contain the microtubule binding regions (Rademakers
et al., 2002) and affect the normal function of tau, i.e., the stabiliza-
tionof microtubules promoting their assembly by binding tubulin.
Some mutations increase the free cytoplasmic portion of the pro-
tein promoting tau aggregation,whereas others lead to an aberrant
phosphorylation of tau protein, which damages microtubule sta-
bilization (Buée and Delacourte, 1999; Goedert and Jakes, 2005).
Otherwise, many other mutations affect the alternative splicing,
thus producing altered ratios of the different isoforms (3R/4R tau;
Goedert et al., 1989). At autopsy, patients with MAPT mutations
show tau-positive inclusions (Rademakers et al., 2004).
The clinical presentation in MAPT mutation carriers in mainly
consistent with bvFTD,with amean onset in the 50s (Yancopoulou
and Spillantini, 2003; Villa et al., 2011). Nevertheless, cases of
PNFA have been reported as well, with an onset even in the sixth
decade of life (Villa et al., 2011).
PROGRANULIN GENE
After the discovery of MAPT as causal gene for FTDP-17, there
were still numerous autosomal dominant FTLD cases genetically
linked to the same chromosomal region of MAPT (chr17q21),
in which no pathogenic mutations had been identiﬁed. A small
region rich of genes, localized approximately 6.2Mb in physical
distance to MAPT locus, had been recognized as that one contain-
ing the gene responsible for the disease in these families. Systematic
sequencing of candidate genes within thisminimal regionwas per-
formed and the ﬁrst mutation in progranulin gene (GRN ) was
identiﬁed. It consists of a 4-bp insertion of CTGC between coding
nucleotides 90 and 91, causing a frameshift and premature termi-
nation in progranulin (C31LfsX34; Baker et al., 2006). Cruts et al.
(2006), analyzing other families with a FTLD pathology without
MAPT mutation, found at the same time another mutation of ﬁve
base pairs into the intron following the ﬁrst non-coding exon of
the gene (IVS0+ 5G–C). This mutation causes the splicing out of
the intron 0, leading the retention of mRNA within the nucleus
and its degradation.
GRN gene encodes for the growth regulation factor progran-
ulin, belonging to a family of proteins involved in many biological
functions including development, wound repair, and inﬂamma-
tion by activating signaling cascades that control cell cycle pro-
gression (He and Bateman, 2003). Progranulin is a 593 amino acid
protein, rich of cysteine with a molecular weight of 68.5 kDa, sub-
jected to proteolysis by elastase in a process regulated by a secretory
leukocyte protease inhibitor (SLPI; Zhu et al., 2002). It is expressed
not only in neurons but also is the activated microglia (Baker et al.,
2006).
Since the original identiﬁcation of null-mutations in FTLD
in 2006, 69 different mutations have been described so far
(http://www.molgen.ua.ac.be/) in 231 families.Most of the known
pathogenic GRN mutations, including frameshift, splice-site, and
nonsense mutations, are predicted to result in a premature stop
codon. The resulting aberrant mRNA is degraded through the
process of nonsense mediated decay, leading to haploinsufﬁciency
(Gass et al., 2006).
Clinically, mutations in GRN are associated with extremely
heterogeneous phenotypes, including, besides the classical FTLD
presentations, AD (Carecchio et al., 2009), corticobasal syndrome
(CBS; Carecchio et al., 2011), or Mild Cognitive Impairment
(Pietroboni et al., 2011). Age at disease onset is extremely wide,
even in the same family (Pietroboni et al., 2011). In addition,
the demonstration of the clinical overlap between psychiatric dis-
orders and genetically determined FTLD comes from the recent
description of a patient with heterosexual pedophilia (Rainero
et al., 2011), who was a carrier of a GRN mutation and devel-
oped bvFTD over time, and from a second description reporting
two clinically different, apparently sporadic FTLD cases sharing
the previously described Thr272fs GRN mutation, who had had a
premorbid bipolar disorder history (Cerami et al., 2011).
A major contribution to achieve a correct diagnosis indepen-
dent of the phenotypic presentation is the demonstration that
progranulin plasma levels are extremely low inGRN mutation car-
riers, even in asymptomatic subjects (Ghidoni et al., 2008; Finch
et al., 2009; Carecchio et al., 2011; Pietroboni et al., 2011).
Notwithstanding the striking proximity of MAPT and GRN on
chromosome 17, at this time, there is no clear link between these
two genes, suggesting that their closeness is just a coincidence.
GRN-mutated FTLD cases at the neuropathological exam-
ination presented ubiquitin immunoreactive cytoplasmic and
intranuclear neuronal inclusions similar to the microvacuolar-
type still observed in a large proportion of apparently sporadic
FTLD, and differing from the tau-positive inclusions typical of
MAPT mutated cases. Soon after the identiﬁcation of GRN
mutation, truncated, and hyperphosphorylated isoforms of the
TAR–DNA binding protein (TDP)-43 were recognized as main
components of the ubiquitin-positive inclusions typical of the
GRN -mutated families, as well as of idiopathic FTLD and of a
proportion of amyotrophic lateral sclerosis (ALS) cases (Neumann
et al., 2006).
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GRN mutations account for about 5–10% of all FTD cases,
markedly varying depending on the population considered (Cruts
et al., 2006; Gass et al., 2006; Snowden et al., 2006). A collabora-
tive study (Yu et al., 2010) analyzing GRN mutations in 434 FTLD
patients, clinically ranging from bvFTD to PNFA, FTLD associ-
ated with parkinsonism or MND, estimates a frequency of 6.9%
of all included FTLD-spectrum cases. In these cases, the 56.2%
was represented by FTLD-U-diagnosed subjects with a known
familial history of FTD, pathologically conﬁrmed. Clinical infor-
mation were available for 31 GRN mutation-positive patients: the
most common phenotype was bvFTD (n = 24), while 3 patients
were diagnosed with PNFA, 3 with AD, and 1 with CBS (Yu et al.,
2010).
CHROMATIN-MODIFYING 2B
Few FTLD families display mutations in the CHMP2B gene,
which encodes a component of the heteromeric endosomal
sorting complex required for transport (ESCRT III complex)
involved in the endosomal trafﬁcking and degradation (Skibin-
ski et al., 2005). To date, only four different mutations between
or in the exons 5 and 6 have been so far described in ﬁve
families (http://www.molgen.ua.ac.be/), making CHMP2B an
extremely rare genetic cause of FTLD pathology. Neuropatholog-
ically, patients with CHMP2B mutations present FTLD-U with
ubiquitin-positive but TDP-43-negative cytoplasmic inclusions
(Holm et al., 2007). Behavioral and cognitive impairment asso-
ciated with extrapyramidal and pyramidal signs are the main
clinical manifestations in CHMP2B mutation carriers. Myoclonus
can occur late in the course of the disease (Gydesen et al., 2002)
and motor neuron disorders have been described in only two cases
(Parkinson et al., 2006).
VALOSIN-CONTAINING PROTEIN-1
Some familial cases having mutations in the VCP-1 gene were
reported (Watts et al., 2004). However, the phenotype associated
with such mutations is inclusion body myopathy, Paget’s disease
of bone and less frequently FTD (IBMPFD; Kimonis et al., 2008).
Myopathy is the more frequent clinical symptom, present in about
90% of affected subjects, whereas FTD is seen in about 30%,
usually many years after the onset of muscle symptoms.
TARDBP
The most common clinical phenotype associated with TARDBP
mutations is ALS, and aggregates made of TDP-43 have been
described in brain and spinal cord of such patients. Neverthe-
less, TARDBP mutated subjects can present also parkinsonism in
association with motor neuron dysfunction (see Pesiridis et al.,
2009 for review). At present,TARDBP mutations have been found
in 5% of familiar ALS and only rarely in FTD and FTD–MND
subjects (Benajiba et al., 2009; Borroni et al., 2009).
Chr 9 HEXANUCLEOTIDE REPETITION
Lastly, one of themost intriguing discovery in the genetics of FTLD
has been the investigation of FTD/MND families linked to a locus
on chromosome 9q21-22. The ﬁrst evidence of linkage with this
locus comes from a study carried out in families with FTD–MND
(Hosler et al., 2000). After some others reports conﬁrming the
linkage to chr9q21-22 in additional FTD–MND families (Morita
et al., 2006; Rollinson et al., 2011), and a search lasting more than
a decade, in 2011, two groups of researchers identiﬁed the gene
responsible for the disease, the chromosome 9 open reading frame
72 (C9ORF72). Both these studies (Dejesus-Hernandez et al., 2011;
Renton et al., 2011) reported a large hexanucleotide (GGGGCC)
repeat expansion in the ﬁrst intron of C9ORF72 as responsible
for a high number of familiar ALS or combined FTD–MND phe-
notype and TDP-43 based pathology. This mutation causes the
loss of one alternatively spliced transcript, whose function is still
unknown, and the formation of nuclear RNA foci. Wild-type alle-
les contain no more than 23–30 repeats, whereas mutated alleles
have more than 100 repeats. These studies thus demonstrated that
C9ORF72 mutation is at present a major cause of both famil-
iar FTD (12%) and ALS (22.5%) cases (Dejesus-Hernandez et al.,
2011),with a higher prevalence in the northern population, reach-
ing a prevalence of 46% of all familiar ALS, 21.1% of sporadic
ALS, and 29.3% of FTD in the Finnish population (Renton et al.,
2011). Clinically, the large clinical series reported in these studies
show that the predominant phenotypes are consistent with bvFTD
and ALS, with different phenotypic presentation even in the same
family (i.e., FTD, ALS, or a combination of both). From the FTD
series reported in Dejesus-Hernandez et al. (2011) study, 26.9%
FTLDcases had concomitantALS andmore than 30%had relatives
affected with ALS.
CONCLUSIVE REMARKS
In the last few years, it has become clear that there are multiple
genetic autosomal dominant mutations leading to the develop-
ment of FTLD. The most frequent are so far MAPT and GRN
mutations that are associated with high phenotypic variability.
Whereas the majority of MAPT mutations is characterized by an
early onset of symptoms and is associated with a clear segregation
across generations, age at disease onset is very wide in GRN muta-
tion carriers. According to the most recent discoveries, the large
hexanucleotide (GGGGCC) repeat expansion in the ﬁrst intron of
C9ORF72 is not only one of themost frequentmutation associated
with ALS and FTD–MND, but is also the second most frequent in
FTLD, after GRN mutations (Gijselinck et al., 2012). Given the
incomplete penetrance of such mutations, a number of cases are
apparently sporadic,making more difﬁcult to suspect the presence
of a causal mutation. Regarding genetic counseling, at present no
international shared guidelines are available.
GENETICS: RISK FACTORS
The ﬁrst candidate-gene studied in FTLD was the well-known risk
factor for late onset sporadic AD,APOE. A number of studies sug-
gested an association between FTLD and APOE∗4 allele (Farrer
et al., 1995; Helisalmi et al., 1996; Gustafson et al., 1997; Stevens
et al., 1997; Fabre et al., 2001; Bernardi et al., 2006). Neverthe-
less, other authors did not replicate these data (Geschwind et al.,
1998; Riemenschneider et al., 2002; Short et al., 2002). Additional
ﬁndings demonstrated an association between the APOE∗4 allele
and FTLD in males, but not females (Srinivasan et al., 2006). An
increased frequency of the APOE∗4 allele has been described in
patients with SD compared to those with FTD and PNFA (Short
et al., 2002).
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Concerning the APOE*2 allele, Bernardi et al. (2006) showed a
protective effect of this allele toward FTLD, whereas other authors
failed to do so (Riemenschneider et al., 2002; Short et al., 2002;
Engelborghs et al., 2003; Srinivasan et al., 2006). A meta-analysis
comprising a total of 364 FTD patients and 2671 controls demon-
strated an increased susceptibility to FTD in APOE*2 carriers
(Verpillat et al., 2002).
Besides pathogenic mutations, several polymorphisms have
been described both in MAPT and GRN. In Baker et al. (1999),
two common MAPT haplotypes, named H1 and H2, were iden-
tiﬁed. They differ in nucleotide sequence and intron size, but are
identical at the amino acid level. Homozygosis of the more com-
mon allele H1 predisposes to Progressive Supranuclear Palsy and
CBS, but not to AD or Pick Disease (Baker et al., 1999; Di Maria
et al., 2000).
A contribution of GRN genetic variability in sporadic FTLD
has previously been shown (Rademakers et al., 2008), even though
another study did not conﬁrm these data (Rollinson et al., 2011). A
further association analysis demonstrated that a single nucleotide
polymorphism (SNP) in the GRN promoter inﬂuences the risk
for FTLD (Galimberti et al., 2010).
A known polymorphism (A-2518G) in monocyte
chemoattractant-1 (MCP-1) gene has been shown to exert a
protective effects toward the development of FTLD (Galimberti
et al., 2009), whereas Nitric Oxide Synthase (NOS)3 G894T
(Glu298Asp) and NOS1 C276T SNPs likely increase the risk to
develop FTLD (Venturelli et al., 2008, 2009). Further genetic
risk factors, discovered on a candidate-gene basis, include BCL2-
associated athanogene 1 (BAG1), an anti-apoptotic factor that
interacts with tau and regulates its proteasomal degradation (Ven-
turelli et al., 2011), KIF24 (Venturelli et al., 2010), and defective in
cullin neddylation 1 (DCN-1)-domain containing 1 (DCUN1D1;
Villa et al., 2009).
Van Deerlin et al. (2010) reported the results of the ﬁrst
genome-wide association study (GWAS) on 515 individuals
affected by FTLD with autopsy-proven TDP-43 inclusions pathol-
ogy (FTLD–TDP) compared with 2509 healthy controls, showing
an associationwith three SNPsmapping to a single linkage disequi-
librium block on 7p21. This region contains the geneTMEM106B,
whose variants may increase the risk to develop the disease by
increasing GRN gene expression.
This association was conﬁrmed in an independent Flanders–
Belgian cohort of FTLD patients (n = 288; van der Zee et al.,
2011). However, these ﬁndings were not conﬁrmed by repli-
cation study performed in two clinical FTLD cohorts of
British origin (Rollinson et al., 2011). Though these authors
failed to detect any association of TMEM106B, the analy-
sis of chromosome 9 locus revealed strong association in the
London FTLD cohort and in the FTLD/ALS cases of the
Manchester cohort, later conﬁrmed with the discovery of the
C9ORF72 gene (Dejesus-Hernandez et al., 2011; Renton et al.,
2011).
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